Last reviewed · How we verify
NCT04561518: ConTTRibute
ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
trial in Transthyretin-Mediated Amyloidosis in 1,500 participants. Currently enrolling.
1 September 2030
Quick facts
| Lead sponsor | Alnylam Pharmaceuticals |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,500 |
| Start date | 23 November 2020 |
| Primary completion | 1 September 2030 |
| Estimated completion | 1 September 2030 |
| Sites | 40 locations across Denmark, France, Italy, Netherlands, Taiwan, Germany, Israel, Bulgaria |
Conditions studied
- Transthyretin-Mediated Amyloidosis — all drugs for Transthyretin-Mediated Amyloidosis →
- ATTR Amyloidosis — all drugs for ATTR Amyloidosis →
Sponsor
Alnylam Pharmaceuticals — full company profile →
Who can join
Eligibility, any sex, with Transthyretin-Mediated Amyloidosis or ATTR Amyloidosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to: * Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients * Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting * Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Therapeutic siRNA: State-of-the-Art and Future Perspectives.
Friedrich M, Aigner A. · · 2022 · cited 256× · PMID 35997897 · DOI 10.1007/s40259-022-00549-3 -
Hepatocyte targeting <i>via</i> the asialoglycoprotein receptor.
Ramírez-Cortés F, Ménová P. · · 2025 · cited 22× · PMID 39628900 · DOI 10.1039/d4md00652f -
Rationale and Design of ANTHOLOGY: An ATTR Amyloidosis Real-World Evidence Program Aiming to Address Gaps in Amyloidosis Care.
Gillmore JD, Hahn K, Smith JG, Conceição I, et al · · 2025 · PMID 40108078 · DOI 10.1007/s40119-025-00402-y
Verify or expand the search:
- PubMed search for NCT04561518
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Alnylam Pharmaceuticals trials
Trials by the same sponsor.
- NCT07535606 — A Study to Evaluate ALN-4915 in Adult Healthy Volunteers · Phase 1 · recruiting
- NCT07463846 — A Study to Evaluate ALN-2232 in Participants With Obesity · Phase 1, PHASE2 · recruiting
- NCT07223203 — TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidos · Phase 3 · recruiting
- NCT07465224 — A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus · Phase 2 · recruiting
- NCT07358078 — DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04561518 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Alnylam Pharmaceuticals
- Last refreshed: 31 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04561518.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing